Results 211 to 220 of about 459,789 (287)

Association Between Point-of-Care Viral Testing for Influenza and Adenovirus and Antibiotic Management in a Pediatric Emergency Department in Italy. [PDF]

Children (Basel)
Bellini T, Lacovara A, Franzone D, Mariani M, Iovinella G, Virgilio M, Lasagna J, Matarese S, Pepino C, Canzoneri F, Guazzi M, Piccotti E, Moscatelli A.   +12 more
europepmc   +1 more source

Current Medical Research Winter 2007/Spring 2008 [PDF]

, 2009
Fehring, Richard
core   +1 more source

Three years of medication-use sequences in incident bipolar disorder in Sweden reveal divergent patterns in native-born and immigrant populations. [PDF]

Transl Psychiatry
Kautzky A, Gémes K, Ármannsdóttir B, Amin R, Akhtar A, Lieslehto J, Tanskanen A, Taipale H, Mittendorfer-Rutz E.   +8 more
europepmc   +1 more source

Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Patients with juvenile idiopathic arthritis (JIA) frequently exhibit antinuclear antibodies (ANAs), but the specific antigen target recognized by them and the presence of additional autoantibody specificities in patients with JIA remains elusive.
Viola Pitkänen, Terhi Remes‐Pakarinen, Paula Vähäsalo, Milja Möttönen, Minna‐Maija Grönlund, Miika Arvonen, Mikael Knip, Riitta Veijola, Jorma Toppari, Jorma Ilonen, Johanna Lempainen, Anna‐Mari Schroderus, Liisa Kröger, Tuure Kinnunen   +13 more
wiley   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Glucocorticoid-induced adrenal insufficiency: physiological dose tapering promotes recovery. [PDF]

Endocr Connect
Mehta R, Lazarus K, Sharma A, Eng PC, Narula K, Choudhury S, Papadopoulou D, Htut Z, Tan TM, Meeran K.   +9 more
europepmc   +1 more source

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers   +33 more
wiley   +1 more source

Clinical trials in small-cell lung cancer treatment: a cross-sectional analysis of trial discontinuation and non-publication. [PDF]

Discov Oncol
Chen H, Lin K, Dai Z, Pan S.
europepmc   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

Capturing durable benefits: interpreting six-year treatment-free survival and restricted mean survival time in CheckMate 227. [PDF]

J Thorac Dis
Kobayashi T, Nakamura S, Hakozaki T.
europepmc   +1 more source